{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:08:48Z","timestamp":1789186128621,"version":"build-2803163510"},"reference-count":32,"publisher":"Japanese Circulation Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2026,9,10]]},"DOI":"10.1253\/circrep.cr-25-0339","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:10:48Z","timestamp":1784844648000},"page":"1543-1551","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Body Mass Index and Cardiac Dysfunction During Human Epidermal Growth Factor Receptor 2 Inhibitor Therapy for Breast Cancer"],"prefix":"10.1253","volume":"8","author":[{"given":"Miharu","family":"Masaki","sequence":"first","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Horie","sequence":"first","affiliation":[{"name":"Medical Research Institute, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Wakasa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Medical Research Institute, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Ishigaki","sequence":"additional","affiliation":[{"name":"Medical Research Institute, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Social and Environmental Medicine, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Inokuchi","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketsugu","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","unstructured":"1. Foundation for Promotion of Cancer Research. Cancer statistics in Japan. 2025. https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/pdf\/cancer_statistics_2025_fig_E.pdf (accessed 1 Aug 2025)."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Liu X, Tao L, Wang M, Li H, Xu W. ABSDELL model: Development and internal validation of a risk prediction model of LVEF decline in breast cancer patients treated with trastuzumab. <i>Clin Breast Cancer<\/i> 2023; 23: 23\u201331, doi:10.1016\/J.CLBC.2022.10.010.","DOI":"10.1016\/j.clbc.2022.10.010"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ross JS, Fletcher JA. The HER-2\/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. <i>Stem Cells<\/i> 1998; 16: 413\u2013428, doi:10.1002\/STEM.160413.","DOI":"10.1002\/stem.160413"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene. <i>Science (1979)<\/i> 1987; 235: 182\u2013191, doi:10.1126\/SCIENCE.3798106.","DOI":"10.1126\/science.3798106"},{"key":"5","unstructured":"5. Valicsek E, Koszo R, Dobi A, Uhercsak G, Varga Z, Vass A, et al. Cardiac surveillance findings during adjuvant and palliative trastuzumab therapy in patients with breast cancer. <i>Anticancer Res<\/i> 2015; 35: 4967\u20134973."},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Ban M, Petri\u0107 Mi\u0161e B, Vrdoljak E. Early HER2-positive breast cancer: Current treatment and novel approaches. <i>Breast Care<\/i> 2020; 15: 560\u2013569, doi:10.1159\/000511883.","DOI":"10.1159\/000511883"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Tesch ME, Gelmon KA. Targeting HER2 in breast cancer: Latest developments on treatment sequencing and the of biosimilars. <i>Drugs<\/i> 2020; 80: 1811\u20131830, doi:10.1007\/S40265-020-01411-Y.","DOI":"10.1007\/s40265-020-01411-y"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Zekri J, Rasool H, Rizvi SAJ, Eldeeb H, Al-Gahmi A, Farag K, et al. Cardiac function in women receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer. <i>Women\u2019s Health<\/i> 2023, doi:10.1177\/17455057231166837.","DOI":"10.1177\/17455057231166837"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Haga F, Oikawa M, Tani T, Yokokawa T, Misaka T, Kaneshiro T, et al. Development of cancer therapy-related cardiac dysfunction is associated with disease progression in breast cancer. <i>Circ Rep<\/i> 2026; 8: 244\u2013253, doi:10.1253\/CIRCREP.CR-25-0220.","DOI":"10.1253\/circrep.CR-25-0220"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: Where these entities intersect: A Scientific Statement from the American Heart Association. <i>Circulation<\/i> 2018; 137: e30\u2013e66, doi:10.1161\/CIR.0000000000000556.","DOI":"10.1161\/CIR.0000000000000556"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Gyawali B, Niraula S. Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials. <i>Cancer Treat Rev<\/i> 2017; 60: 18\u201323, doi:10.1016\/J.CTRV.2017.08.001.","DOI":"10.1016\/j.ctrv.2017.08.001"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Sardesai S, Sukumar J, Kassem M, Palettas M, Stephens J, Morgan E, et al. Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer. <i>Cardiooncology<\/i> 2020 6: 26, doi:10.1186\/S40959-020-00081-9.","DOI":"10.1186\/s40959-020-00081-9"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Barron CC, Tyagi NK, Alhussein MM, Mukherjee SD, Ellis PM, Dhesy-Thind S, et al. Adjuvant trastuzumab therapy: Can we balance efficacy and safety? <i>Oncologist<\/i> 2019; 24: 1405\u20131409, doi:10.1634\/THEONCOLOGIST.2019-0263.","DOI":"10.1634\/theoncologist.2019-0263"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Barron CC, Alhussein MM, Kaur U, Cosman TL, Tyagi NK, Brown M, et al. An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction. <i>Curr Oncol<\/i> 2019; 26: 240\u2013246, doi:10.3747\/CO.26.4631.","DOI":"10.3747\/co.26.4631"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Lyon AR, L\u00f3pez-Fern\u00e1nde T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klei J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J<\/i> 2022; 43: 4229\u20134361, doi:10.1093\/EURHEARTJ\/EHAC244.","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Zhou S, Cirne F, Chow J, Zereshkian A, Bordeleau L, Dhesy-Thind S, et al. Three-year outcomes following permissive cardiotoxicity in patients on trastuzumab. <i>Oncologist<\/i> 2023; 28: e712\u2013e722, doi:10.1093\/ONCOLO\/OYAD086.","DOI":"10.1093\/oncolo\/oyad086"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials.  <i>Cancer<\/i> 2003; 97: 2869\u20132879, doi:10.1002\/CNCR.11407.","DOI":"10.1002\/cncr.11407"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. <i>Lancet<\/i> 2007; 369: 29\u201336, doi:10.1016\/S0140-6736(07)60028-2.","DOI":"10.1016\/S0140-6736(07)60028-2"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Yoon HJ, Kim KH, Kim JY, Park HJ, Cho JY, Hong YJ, et al. Chemotherapy-induced left ventricular dysfunction in patients with breast cancer. <i>J Breast Cancer<\/i> 2016; 19: 402\u2013409, doi:10.4048\/JBC.2016.19.4.402.","DOI":"10.4048\/jbc.2016.19.4.402"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Grela-Wojewoda A, P\u00fcsk\u00fcll\u00fco\u011flu M, Sas-Korczy\u0144ska B, Zeme\u0142ka T, Pacholczak-Madej R, Wysocki WM, et al. Biomarkers of trastuzumab-induced cardiac toxicity in HER2-positive breast cancer patient population. <i>Cancers (Basel)<\/i> 2022; 14: 3353, doi:10.3390\/CANCERS14143353.","DOI":"10.3390\/cancers14143353"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. \u00d6zcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, H\u00fcbner N, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. <i>Proc Natl Acad Sci U S A<\/i> 2002; 99: 8880\u20138885, doi:10.1073\/PNAS.122249299.","DOI":"10.1073\/pnas.122249299"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Kenchaiah S, Sesso HD, Gaziano JM. Body mass index and vigorous physical activity and the risk of heart failure among men. <i>Circulation<\/i> 2009; 119: 44\u201352, doi:10.1161\/CIRCULATIONAHA.108.807289.","DOI":"10.1161\/CIRCULATIONAHA.108.807289"},{"key":"23","unstructured":"23. Kenchaiah S, Chesebro JH. The epidemiologic association between obesity and heart failure. <i>Am Coll Cardiol Ext Learn<\/i> 2017; 49: 4."},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Kabor\u00e9 EG, Guenancia C, Vaz-Luis I, Di Meglio A, Pistilli B, Coutant C, et al. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. <i>PLoS Med<\/i> 2019; 16: e1002989, doi:10.1371\/JOURNAL.PMED.1002989.","DOI":"10.1371\/journal.pmed.1002989"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Shinano H, Miyazaki S, Miura K, Ohtsu H, Yonemoto N, Matsuoka K, et al. Risk profiling of cancer treatment-related cardiovascular disorders in breast cancer patients who received adjuvant chemotherapy with trastuzumab. <i>Circ Rep<\/i> 2020; 2: 235\u2013242, doi:10.1253\/CIRCREP.CR-19-0119.","DOI":"10.1253\/circrep.CR-19-0119"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. <i>J Am Coll Cardiol<\/i> 2009; 53: 2231\u20132247, doi:10.1016\/J.JACC.2009.02.050.","DOI":"10.1016\/j.jacc.2009.02.050"},{"key":"27","unstructured":"27. Okada Y, Okura Y, Kanbayashi C, Sato N. Clinical characteristics of trastuzumab-associated cardiac dysfunction. <i>J Cardiol Jpn Ed<\/i> 2010; 5: 6\u201312."},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Liu FF, Stone JR, Schuldt AJT, Okoshi K, Okoshi MP, Nakayama M, et al. Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. <i>Am J Physiol Heart Circ Physiol<\/i> 2005; 289: H660\u2013H666, doi:10.1152\/AJPHEART.00268.2005.","DOI":"10.1152\/ajpheart.00268.2005"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Liu X, Gu X, Li Z, Li X, Li H, Chang J, et al. Neuregulin-1\/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2006; 48: 1438\u20131447, doi:10.1016\/J.JACC.2006.05.057.","DOI":"10.1016\/j.jacc.2006.05.057"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. de Korte MA, de Vries EGE, Lub-de Hooge MN, Jager PL, Gietema JA, van der Graaf WTA, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. <i>Eur J Cancer<\/i> 2007; 43: 2046\u20132051, doi:10.1016\/J.EJCA.2007.06.024.","DOI":"10.1016\/j.ejca.2007.06.024"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Lamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. <i>N Engl J Med<\/i> 2001; 344: 783\u2013792, doi:10.1056\/NEJM200103153441101.","DOI":"10.1056\/NEJM200103153441101"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Hwang HJ, Han SA, Sohn IS. Breast cancer and therapy-related cardiovascular toxicity. <i>J Breast Cancer<\/i> 2024; 27: 147\u2013162, doi:10.4048\/JBC.2024.0085.","DOI":"10.4048\/jbc.2024.0085"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/9\/8_CR-25-0339\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:25:23Z","timestamp":1789183523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/9\/8_CR-25-0339\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-25-0339","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"CR-25-0339"}}